Skip to main content
Top
Published in: Abdominal Radiology 3/2019

01-03-2019 | Pancreas

Pancreatic neuroendocrine tumors: MR imaging features preoperatively predict lymph node metastasis

Authors: Haitao Sun, Jianjun Zhou, Kai Liu, Tingting Shen, Xingxing Wang, Xiaolin Wang

Published in: Abdominal Radiology | Issue 3/2019

Login to get access

Abstract

Purposes

Predictive factors of lymph node metastasis (LNM) in pancreatic neuroendocrine tumors (pNETs) are not well established. We sought to identify the value of MR imaging features in preoperatively predicting the lymph node metastasis of pNETs.

Materials and methods

In this study, we enrolled 108 consecutive patients with pNETs between January 2009 and June 2018. MR morphologic features and quantitative data were evaluated. Predictors of LNM were evaluated using univariate and multivariate logistic regression models.

Results

A total of 108 patients with pNETs were finally enrolled, including 82 LNM-negative and 26 LNM-positive patients. Features significantly related to the LNM of pNETs at univariate analysis were tumor size > 2 cm (P = 0.003), Ki-67 > 5% (P = 0.002), non-enhancement pattern (P < 0.001), apparent diffusion coefficient value (P < 0.001), main pancreatic duct dilation (P < 0.001) and pancreatic atrophy (P = 0.032) and extrapancreatic tumor spread (P = 0.001), CNRs during arterial, portal and delay phase (P = 0.005, 0.047, and 0.045, respectively), and histological classification (P = 0.006). At multivariate analysis, non-enhancement pattern (P = 0.019; odds ratio, 6.652; 95% CI 1.369, 32.321) and main pancreatic duct dilation (P = 0.018; odds ratio, 6.745; 95% CI 1.379, 32.991) were independent risk factors for predicting the LNM of pNETs.

Conclusion

The non-enhancement characteristic and main pancreatic duct dilation appear to be linked with LNM in pNETs. These radiological predictors can be easily obtained preoperatively, and may help to avoid missing pNETs with a high risk of LNM.
Literature
1.
go back to reference Kartalis N, Mucelli RM, Sundin A. (2015) Recent developments in imaging of pancreatic neuroendocrine tumors. Ann Gastroenterol 28: 193-202PubMedPubMedCentral Kartalis N, Mucelli RM, Sundin A. (2015) Recent developments in imaging of pancreatic neuroendocrine tumors. Ann Gastroenterol 28: 193-202PubMedPubMedCentral
3.
go back to reference Rindi G, Kloppel G, Alhman H, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401CrossRefPubMedPubMedCentral Rindi G, Kloppel G, Alhman H, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401CrossRefPubMedPubMedCentral
4.
go back to reference Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. (2015) Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl) 128: 3335-44CrossRef Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. (2015) Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl) 128: 3335-44CrossRef
5.
go back to reference Hashim YM, Trinkaus KM, Linehan DC, et al. (2014) Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 259: 197-203CrossRefPubMedPubMedCentral Hashim YM, Trinkaus KM, Linehan DC, et al. (2014) Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 259: 197-203CrossRefPubMedPubMedCentral
6.
go back to reference De Robertis R, Maris B, Cardobi N, et al. (2018) Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol 28: 2582-2591CrossRefPubMed De Robertis R, Maris B, Cardobi N, et al. (2018) Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol 28: 2582-2591CrossRefPubMed
7.
go back to reference Lotfalizadeh E, Ronot M, Wagner M, et al. (2017) Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol 27: 1748-1759CrossRefPubMed Lotfalizadeh E, Ronot M, Wagner M, et al. (2017) Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol 27: 1748-1759CrossRefPubMed
8.
go back to reference Wang Y, Chen ZE, Yaghmai V, et al. (2011) Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 33: 1071-9CrossRefPubMed Wang Y, Chen ZE, Yaghmai V, et al. (2011) Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 33: 1071-9CrossRefPubMed
9.
go back to reference Jeon SK, Lee JM, Joo I, et al. (2017) Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study. Radiology 284: 77-87CrossRefPubMed Jeon SK, Lee JM, Joo I, et al. (2017) Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study. Radiology 284: 77-87CrossRefPubMed
10.
go back to reference Nanno Y, Toyama H, Otani K, et al. (2016) Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology 16: 882-7CrossRefPubMed Nanno Y, Toyama H, Otani K, et al. (2016) Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology 16: 882-7CrossRefPubMed
11.
go back to reference Curran T, Pockaj BA, Gray RJ, et al. (2015) Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg 19: 152-60CrossRefPubMed Curran T, Pockaj BA, Gray RJ, et al. (2015) Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg 19: 152-60CrossRefPubMed
12.
go back to reference Taki K, Hashimoto D, Nakagawa S, et al. (2017) Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surg Today 47: 1104-1110CrossRefPubMed Taki K, Hashimoto D, Nakagawa S, et al. (2017) Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surg Today 47: 1104-1110CrossRefPubMed
13.
go back to reference Mizumoto T, Toyama H, Terai S, et al. (2017) Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology 17: 956-961CrossRefPubMed Mizumoto T, Toyama H, Terai S, et al. (2017) Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology 17: 956-961CrossRefPubMed
14.
go back to reference Boninsegna L, Panzuto F, Partelli S, et al. (2012) Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. European Journal of Cancer 48: 1608-1615CrossRefPubMed Boninsegna L, Panzuto F, Partelli S, et al. (2012) Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. European Journal of Cancer 48: 1608-1615CrossRefPubMed
15.
go back to reference Bettini R, Partelli S, Boninsegna L, et al. (2011) Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150: 75-82CrossRefPubMed Bettini R, Partelli S, Boninsegna L, et al. (2011) Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150: 75-82CrossRefPubMed
16.
go back to reference Jiang Y, Jin JB, Zhan Q, et al. (2015) Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl) 128: 3335-44CrossRef Jiang Y, Jin JB, Zhan Q, et al. (2015) Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl) 128: 3335-44CrossRef
17.
go back to reference Parekh JR, Wang SC, Bergsland EK, et al. (2012) Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 41: 840-4CrossRefPubMed Parekh JR, Wang SC, Bergsland EK, et al. (2012) Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 41: 840-4CrossRefPubMed
18.
go back to reference Gratian L, Pura J, Dinan M, et al. (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21: 3515-21CrossRefPubMedPubMedCentral Gratian L, Pura J, Dinan M, et al. (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21: 3515-21CrossRefPubMedPubMedCentral
19.
go back to reference Postlewait LM, Ethun CG, Baptiste GG, et al. (2016) Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol 114: 440-5CrossRefPubMed Postlewait LM, Ethun CG, Baptiste GG, et al. (2016) Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol 114: 440-5CrossRefPubMed
20.
go back to reference Rodallec M, Vilgrain V, Couvelard A, et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6: 77-85CrossRefPubMed Rodallec M, Vilgrain V, Couvelard A, et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6: 77-85CrossRefPubMed
21.
go back to reference Worhunsky DJ, Krampitz GW, Poullos PD, et al. (2014) Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) 16: 304-11CrossRef Worhunsky DJ, Krampitz GW, Poullos PD, et al. (2014) Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) 16: 304-11CrossRef
22.
go back to reference Hyodo R, Suzuki K, Ogawa H, et al. (2015) Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading. Eur J Radiol 84: 2103-9CrossRefPubMed Hyodo R, Suzuki K, Ogawa H, et al. (2015) Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading. Eur J Radiol 84: 2103-9CrossRefPubMed
23.
go back to reference Kim JH, Eun HW, Kim YJ, et al. (2016) Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26: 1338-47CrossRefPubMed Kim JH, Eun HW, Kim YJ, et al. (2016) Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 26: 1338-47CrossRefPubMed
24.
go back to reference Nanno Y, Matsumoto I, Zen Y, et al. (2017) Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann Surg Oncol 24: 1127-1133CrossRefPubMed Nanno Y, Matsumoto I, Zen Y, et al. (2017) Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann Surg Oncol 24: 1127-1133CrossRefPubMed
Metadata
Title
Pancreatic neuroendocrine tumors: MR imaging features preoperatively predict lymph node metastasis
Authors
Haitao Sun
Jianjun Zhou
Kai Liu
Tingting Shen
Xingxing Wang
Xiaolin Wang
Publication date
01-03-2019
Publisher
Springer US
Published in
Abdominal Radiology / Issue 3/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1863-y

Other articles of this Issue 3/2019

Abdominal Radiology 3/2019 Go to the issue

Classics in Abdominal Radiology

The Courvoisier’s sign

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine